Analyst RatingAnalyst maintains a BUY rating and raises the 12-month price target to $2.75, suggesting significant upside from the current share price.
Market PotentialThe potential billion-dollar market for PURE EP presents high rewards for the risks, making an investment in BioSig compelling.
Product InnovationThe PURE EP system, a non-invasive class II device, is designed to provide essential diagnostic signals during cardiac catheter ablations, improving procedure precision.